2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Presentation Webcast Excel
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Presentation Webcast Excel
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Presentation Webcast Excel
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population PDF PDF Presentation Webcast Excel
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study PDF Presentation Webcast Excel
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Presentation Webcast Excel
2022-03-02 | Issue and repurchase of series C shares for share saving program PDF Presentation Webcast Excel
2022-02-15 | Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR conference PDF Presentation Webcast Excel
2021-12-16 | Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial PDF Presentation Webcast Excel
2021-12-01 | Results from Orviglance comparison study to gadolinium presented at RSNA 2021 PDF PDF Presentation Webcast Excel
Regulatory 2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB PDF Presentation Webcast Excel
2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed PDF Presentation Webcast Excel
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® PDF Presentation Webcast Excel
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study PDF Presentation Webcast Excel
2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA PDF Presentation Webcast Excel
2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance PDF Presentation Webcast Excel
Regulatory 2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021 PDF Presentation Webcast Excel
